Drug Profile
XEL 1000
Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Xellia Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cystic-fibrosis-associated-respiratory-tract-infections in Norway (Parenteral, Inhalant)
- 06 Sep 2018 Xellia Pharmaceuticals in-licenses SPS® (Stabilising and Protecting Solutions) formulation technology platform from LEUKOCARE
- 21 Dec 2015 Clinical trials in Cystic fibrosis-associated respiratory tract infections in Norway (Parenteral)